Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849383 | 0.91 | CHRM1 (0.42) | CHRM1CHRM4CHRM5 | |
| SCHEMBL17458677 | 0.90 | LMNA (0.37) | CHRM1CHRM4CHRM5KCNH2 | |
| SCHEMBL17061265 | 0.89 | CHRM1 (0.52) | CHRM1KCNH2 | |
| SCHEMBL7055895 | 0.87 | CHRM1 (0.41) | CHRM1CHRM4CHRM5KCNH2 | |
| SCHEMBL17061337 | 0.85 | AGTR2 (0.52) | CHRM1CHRM4CHRM5KCNH2 | |
| SCHEMBL22332138 | 0.81 | CHRM1 (0.50) | CHRM1KCNH2 | |
| SCHEMBL22332137 | 0.81 | CHRM1 (0.50) | CHRM1KCNH2 | |
| SCHEMBL22837941 | 0.81 | CHRM1 (0.50) | CHRM1KCNH2 | |
| SCHEMBL22957230 | 0.81 | CHRM1 (0.50) | CHRM1KCNH2 | |
| SCHEMBL22332139 | 0.81 | CHRM1 (0.50) | CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7022706-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CLARK THOMAS JEFFREY (US) | 2004-08-05 | — | — | US | disclosed |
| US-20030236405-A1 | A nicotinic acetylcholine receptors, treating neurological and psychological disorders inflamnmatory bowel disease, irritable bowel syndrome, spastic dystonia, pain, vasoconstriction, anxiety, autism, depression, bipolar disorder | YOHANNES DANIEL (US) | 2003-12-25 | — | — | US | disclosed |
| US-6624167-B1 | Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6579878-B1 | 2-((3-pyridyl)methyl)-7-azabicyclo(2.2.1)heptane; agonists of nicotinic cholinergic receptors; dysfunction of the central and autonomic nervous systems | TARGACEPT, INC. | 2003-06-17 | — | — | US | disclosed |
| EP-1305316-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | Targacept, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002004442-A9 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT INC (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020038028-A1 | For therapy of neurological and psychological disorders are claimed. | YOHANNES DANIEL (US) | 2002-03-28 | — | — | US | disclosed |
| US-20020035262-A1 | 7-hetero-bicyclo[2.2.1]-heptanes | YOHANNES DANIEL (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002012245-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | TARGACEPT, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002004442-A2 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0955301-A2 | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors | Pfizer Products Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CHRM1 317/4885CHRM4 246/4885CHRM5 145/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | CHRM1 317/4885CHRM4 246/4885CHRM5 145/4885 |
| US-20020038028-A1 | For therapy of neurological and psychological disorders are claimed. | GRIN2C, PNMT, GRIA4 | CHRM1 465/4885CHRM4 461/4885CHRM5 464/4885 |
| US-20030236405-A1 | A nicotinic acetylcholine receptors, treating neurological and psychological disorders inflamnmatory bowel disease, irritable bowel syndrome, spastic dystonia, pain, vasoconstriction, anxiety, autism, depression, bipolar disorder | CHRNA1, CHRNA6, CHRNA2 | CHRM1 15/4885CHRM4 21/4885CHRM5 16/4885 |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CHRNA7, CHRNA10, CHRNG | CHRM1 22/4885CHRM4 21/4885CHRM5 10/4885 |
| US-20020035262-A1 | 7-hetero-bicyclo[2.2.1]-heptanes | GRIN2C, CYP8B1, CYP11B2 | CHRM1 431/4885CHRM4 717/4885CHRM5 576/4885 |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | AADAC, CYP3A7, CYP3A5 | CHRM1 451/4885CHRM4 425/4885CHRM5 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.